TY - JOUR
T1 - Sporadic versus Tuberous Sclerosis Complex–Associated Angiomyolipomas
T2 - Predictors for Long-Term Outcomes following Transcatheter Embolization
AU - Sheth, Rahul A.
AU - Feldman, Adam S.
AU - Paul, Elahna
AU - Thiele, Elizabeth A.
AU - Walker, T. Gregory
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Purpose To evaluate risk factors for long-term outcomes following embolization of sporadic versus tuberous sclerosis complex (TSC)–associated angiomyolipomas (AMLs). Materials and Methods A retrospective review of consecutive transcatheter embolizations of renal AMLs between 2002 and 2014 was performed. Tumor volumetrics including density analysis were obtained. Treatment outcomes were assessed at 1 year after embolization using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and volumetric RECIST criteria. A total of 56 patients, 70% (39/56) of whom had TSC, underwent embolization of 72 renal AMLs. Embolization was most commonly performed (70/72, 97%) using microspheres (300–500 μm or 500–700 μm Embosphere). Results Between the sporadic and TSC-associated populations, there was no difference in follow-up time (648 d vs 583 d, P = .78), initial tumor diameter (6.68 cm vs 5.71 cm, P = .09), or percent tumoral fat content (39.5% vs 8.6%, P = .35). Progressive disease was noted in 9 TSC-associated AMLs by volume and 3 TSC-associated AMLs by diameter but in no sporadic AMLs. Growth suppression curves were remarkable for rebound growth in TSC patients, particularly in TSC patients younger than 18 years. Patient age (P = .007) and tumor volume (P = .03) were found to correlate with tumor regrowth within the TSC population. No difference was found in median change in total volume after embolization based on fat content (−57.9% vs −54.2%, P = .68). Conclusions TSC, patient age, and tumoral volume before embolization are risk factors for AML growth following embolization. Intratumoral fat content was not found to predict response to embolization.
AB - Purpose To evaluate risk factors for long-term outcomes following embolization of sporadic versus tuberous sclerosis complex (TSC)–associated angiomyolipomas (AMLs). Materials and Methods A retrospective review of consecutive transcatheter embolizations of renal AMLs between 2002 and 2014 was performed. Tumor volumetrics including density analysis were obtained. Treatment outcomes were assessed at 1 year after embolization using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and volumetric RECIST criteria. A total of 56 patients, 70% (39/56) of whom had TSC, underwent embolization of 72 renal AMLs. Embolization was most commonly performed (70/72, 97%) using microspheres (300–500 μm or 500–700 μm Embosphere). Results Between the sporadic and TSC-associated populations, there was no difference in follow-up time (648 d vs 583 d, P = .78), initial tumor diameter (6.68 cm vs 5.71 cm, P = .09), or percent tumoral fat content (39.5% vs 8.6%, P = .35). Progressive disease was noted in 9 TSC-associated AMLs by volume and 3 TSC-associated AMLs by diameter but in no sporadic AMLs. Growth suppression curves were remarkable for rebound growth in TSC patients, particularly in TSC patients younger than 18 years. Patient age (P = .007) and tumor volume (P = .03) were found to correlate with tumor regrowth within the TSC population. No difference was found in median change in total volume after embolization based on fat content (−57.9% vs −54.2%, P = .68). Conclusions TSC, patient age, and tumoral volume before embolization are risk factors for AML growth following embolization. Intratumoral fat content was not found to predict response to embolization.
UR - http://www.scopus.com/inward/record.url?scp=84994372743&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994372743&partnerID=8YFLogxK
U2 - 10.1016/j.jvir.2016.05.029
DO - 10.1016/j.jvir.2016.05.029
M3 - Article
C2 - 27522275
AN - SCOPUS:84994372743
SN - 1051-0443
VL - 27
SP - 1542
EP - 1549
JO - Journal of Vascular and Interventional Radiology
JF - Journal of Vascular and Interventional Radiology
IS - 10
ER -